Obtained drug clinical trial approval notice
April 15, 2025
Source: drugdu
92
Hengrui Medicine announced on the evening of April 13 that the company received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration for HRS-9190 for injection, and will conduct clinical trials in the near future. HRS-9190 for injection is a Class 1 new drug for intraoperative medication, used for tracheal intubation during the induction period of general anesthesia and maintaining skeletal muscle relaxation during surgery. The company announced on the same day that its subsidiaries Shanghai Hengrui Medicine Co., Ltd. and Suzhou Shengdia Biotechnology Co., Ltd. received the "Notice of Approval for Clinical Trial of Drugs" issued by the National Medical Products Administration for SHR-3792 injection, and will conduct clinical trials in the near future. SHR-3792 injection is an innovative anti-tumor drug candidate independently developed by the company, which has shown good anti-tumor activity in preclinical animal models. Upon inquiry, no similar drugs have been approved for marketing at home and abroad.
https://finance.eastmoney.com/a/202504133375232889.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Changshan Pharmaceutical’s Nadroparin Calcium Injection Obtains Belarus Drug Registration Certificate May 22, 2025
- Beihai Kangcheng’s Velaglucerase β for Injection is Approved for Marketing in China May 22, 2025
- FDA filing is about to start, and one medical device has completed its first human clinical trial May 22, 2025
- Phase I clinical drugs can bypass the FDA and go directly to market May 22, 2025
- Gut bacteria help ease chemotherapy side effects and aid recovery May 22, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
